



Track 2- Annual Meetings: Submission Deadlines, Areas of Interest & Educational Goals

In order to submit a request for general meeting support through Track 2- Annual Meetings the answer to the following questions must be “Yes”:

- Does the activity align with Pfizer’s areas of interest? *(listed on pages 2-9 of this document)*
- Is it a live\* **annual** activity which serves as a platform for the exchange of new clinical and scientific information and reaches an international, national, or regional audience?  
*\*Live CME/CE activities are defined as any activity which incorporates the opportunity for live real-time learner interaction such as live meetings, e-learning and live non-enduring web-casts/webinars*
- Is this activity developed by your organization specifically for your professional members or constituents?
- Is the activity established part of your organization’s ongoing educational program? If not, if it is a new activity, is it clearly based on an assessment of the educational needs of your target audience?

Application Cycle	To Submit Live Activity Must Start On or After	Decision Communicated By*
Jan 1 - Feb 15	Apr 1	Mar 11
Mar 1 - Apr 15	Jun 1	May 13
May 1 - June 15	Aug 1	July 15
July 1 - Aug 15	Oct 1	Sept 16
Sept 1 - Oct 31	Dec 1	Nov 18

If your activity is in.....	Latest* Date to submit to Pfizer is....
April or May 2016	February 15
June or July 2016	April 15
August or September 2016	June 15
October or November 2016	August 15
December 2016 or January, February or March 2017	October 31
<i>*This is the latest date to submit. Your request will be reviewed if submitted in an earlier cycle.</i>	

Questions? Email [IGLC@pfizer.com](mailto:IGLC@pfizer.com)

**Acromegaly**

Improve the knowledge base of health care providers, educators and third party payers working in the area of acromegaly.

**Acute Kidney Injury**

Close gaps in knowledge for the progression of the pathophysiology, clinical manifestations and survival.

**Alzheimer's Disease**

Advance learning regarding advances in Alzheimer's Disease research, evolving disease definition, next generation treatment development, identification of new biomarkers, advances in clinical trials, patient care, and clinical assessment tools.

**Attention Deficit Hyperactivity Disorder (ADHD)**

Improve the healthcare providers' understanding of the appropriate diagnosis, treatment and management of ADHD in children through to adulthood within the primary and specialty care settings.

**Biosimilars (Inflammation and Oncology)**

- Improve clinicians' capabilities of discussing complex concepts of biosimilars in basic terms for patients.
- Improve the prudent use of biologic drugs by
  - Increasing awareness of the regulations surrounding biosimilars
  - Increasing awareness of FDA purple book
  - Increasing the percentage of institutions that adopt specific guidelines for addressing biosimilars and biologics

**Cardiovascular Metabolic Risk**

**Cardiovascular Risk Reduction: Focus on Lipids**

- For research clinicians and scientists, facilitate scientific dialogue and the exchange of new research and data in the area of lipid lowering, including PCSK9 inhibition
- For healthcare providers working in the areas of primary care, cardiology, lipidology, and endocrinology, increase the awareness and understanding of:
  - the significant CV risk that persists despite using the current lipid lowering standard of care, with a focus on patients at high CV risk, heterozygous familial hypercholesterolemia (FH), as well as statin intolerant patients, and
  - the new emerging research and mechanisms of action in the area of lipid lowering, including PCSK9 inhibition
  - the importance of CV outcomes evidence to validate new mechanisms in lipid lowering

**Diabetes and Obesity**

Improve healthcare provider awareness of current and emerging evidence-based treatments for diabetic and/or obese patients, and also for patients at risk of developing these diseases.

**Smoking Cessation**

Increase the number of patients who stop smoking by improving the frequency and effectiveness of smoking cessation intervention, including treatment, counseling and support, by healthcare providers.

**Cystic Fibrosis**

Improve the understanding of the progression of the pathophysiology and clinical manifestations.

**Dermatology**

**Atopic Dermatitis**

Improve the care of patients manifesting atopic dermatitis (AD) by increasing healthcare provider knowledge of the disease state or unmet need and the emerging strategies for treatment of AD.

**Inflammatory Diseases such as Alopecia and Vitiligo**

For dermatologists and all healthcare professionals involved in the care and treatment of patients suffering from dermatologic conditions such as alopecia and vitiligo, increase the awareness and understanding of the latest emerging research, ongoing clinical trials, and mechanisms-of-action of new medicines for the treatment of dermatologic conditions.

**Psoriatic Arthritis**

Improve the care of patients with psoriatic arthritis by increasing healthcare provider knowledge of the pathophysiology of psoriatic arthritis, as well as its implications for mechanism of action of emerging therapies.

**Diabetic Peripheral Neuropathy**

Translate knowledge of the consequences of Diabetic Peripheral Neuropathy (DPN) into effective treatment strategies that are appropriate in the context of overall diabetes management.

**Dietary Supplements**

- Improve the healthcare provider's ability to advise and counsel patients on the prevalence of nutritional gaps even amongst consumers with a healthy diet and the roles of MVMs designed to fill nutritional gaps
- Increase the healthcare provider's ability to advise and counsel patients on the importance of diet and nutrition, particularly in the areas of bone, muscle and joint health. To educate physicians on prevalence of osteoporosis and importance of maintaining mobility.

**Duchenne Muscular Dystrophy**

Close knowledge gaps regarding the progression of the pathophysiology and clinical manifestations.

**Fibromyalgia**

Improve awareness of appropriate evidence-based treatment as well as the management of patient expectations in improving patient outcomes for fibromyalgia.

**Friedreich's Ataxia**

Improve the understanding of the progression of the pathophysiology and clinical manifestations.

**Gene Therapy**

Close knowledge gaps regarding gene therapy applications for Cystic Fibrosis, Duchenne Muscular Dystrophy, Friedreich's Ataxia, Hemophilia and Spinal Muscular Atrophy.

**Growth Hormone Deficiency**

Improve the knowledge base of health care providers, educators and third party payers working in the area of GHD.

**Hemophilia**

Facilitate enhanced coordination of care and communications between patients with clotting or bleeding disorders, including hemophilia, and their doctors, and ensure practitioners know how to safely treat and monitor these patients.

**Huntington's Disease**

Improve the understanding of the progression of the pathophysiology and clinical manifestations.

**Infectious Disease**

**Vaccine Preventable Diseases**

- Improve immunization across the life span by addressing perceptions of younger healthcare providers related to immunizations in general.
- Improve the care of pediatric patients by
  - o Highlighting the disparity between family physicians and pediatricians in adherence to recommended childhood vaccination schedule
  - o Addressing barriers to vaccination and series completion with a focus on lower socioeconomic groups and other under-immunized populations
  - o Assessing how barriers can be overcome in the current medical system where making changes in the practice is often difficult given the current bureaucratic structure of many practices and the demands on HCP time
  - o Exploring gaps in the healthcare system that negatively impact the burden of invasive pneumococcal disease and search for ways to minimize these gaps
- Improve the care of adolescent/young adult patients by
  - o Increasing awareness of the changing epidemiology as well as the morbidity and mortality of meningococcal disease in adolescents
  - o Increasing awareness and the percentage of adolescent /young adults receiving and completing national vaccination guideline recommended immunizations
  - o Increasing insights and education on navigating through the potential challenges with Category B recommendations for MnB vaccines, including identification of appropriate patients, implementation of vaccine guidelines, and best practices
  - o Assessing potential for inequitable/tiered vaccine access resulting from fully- vs. under-informed practitioners, ability to communicate risk of MnB disease, and vaccine utilization based upon socioeconomic status and other demographic characteristics
- Improve the care of adult patients by
  - o Increasing awareness of the changing epidemiology of pneumococcal disease in adults
  - o Increasing awareness of national adult vaccination guidelines
  - o Increasing the percentage of adults receiving national guideline recommended immunizations

**Inflammatory bowel disease (IBD)**

Improve the care of patients with inflammatory bowel disease (IBD) by increasing healthcare provider knowledge of the emerging strategies for treatment of IBD.

### **Lysosomal Storage Diseases**

Improve positive outcomes in patients with Lysosomal Storage Diseases by facilitating enhanced coordination of care and communication between multidisciplinary teams of healthcare professionals, ensuring practitioners know how to safely treat and monitor patients.

### **Migraine**

Improve the healthcare provider's understanding of the diagnosis and treatment of Migraine.

### **Oncology**

#### **Acute Lymphoblastic Leukemia (ALL)**

For hematologists, oncologists, transplant physicians, and all healthcare professionals involved in the care and treatment of patients with ALL, increase the awareness and understanding of the latest emerging research, ongoing clinical trials, and the potential use of novel targeted agents for the treatment of ALL, either alone or in combination with chemotherapy.

#### **Breast Cancer**

For oncologists and all healthcare professionals involved in the care and treatment of patients with advanced or metastatic breast cancer, increase the awareness and understanding of the latest emerging research, ongoing clinical trials, and mechanisms-of-action of new medicines for the treatment of metastatic breast cancer; in particular ER+ cancer and advances in CDK 4/6 inhibition.

#### **Chronic Myelogenous Leukemia (CML)**

For hematologists, oncologists and all healthcare professionals involved in the care and treatment of patients with CML, increase understanding of the importance of achieving optimal treatment response through adequate patient monitoring, improve their ability to maintain patient on treatment by proactive and reactive adverse events management, optimize treatment sequencing, and improve patient outcomes.

#### **Gastrointestinal Stromal Tumors (GIST) and Pancreatic Neuroendocrine Tumors (pNET)**

For oncologists and all healthcare professionals involved in the care and treatment of patients with GIST or pNET, increase understanding of when novel targeted therapies should be considered for patients with progressive or advanced disease.

#### **Immuno-Oncology (IO)**

For medical oncologists and all healthcare professionals involved in the care and treatment of patients with Merkel Cell Carcinoma, Ovarian Cancer, NSCLC and/or Gastric Cancer, increase understanding of the rationale for novel IO strategies such as anti-PD-1/PD-L1 therapy and increase awareness of when immunotherapy should be considered as a treatment option for their patients.

**Non-Small Cell Lung Cancer (NSCLC)**

For oncologists, pulmonologists, pathologists, surgeons, interventional radiologists, and all healthcare professionals involved in the care and treatment of patients with NSCLC, increase the awareness and understanding of the importance of treating patients based on the timely results of molecular testing (e.g. ALK, EGFR, ROS1) in order to optimize patient outcomes.

**Renal Cell Carcinoma (RCC)**

For oncologists, urologists and all healthcare professionals involved in the care and treatment of patients with advanced RCC, increase awareness of the evolving treatment landscape and clinical trial results, and also improve clinical competence in applying this information to patient care, especially with respect to sequencing, scheduling, dosing, use of combination therapies, and management of side effects.

**General Oncology - Basic Science and Clinical Research Interests**

Through the academic exchange of research and ideas, enhance the discovery and translation of novel cancer therapies, increase scientific understanding of their mechanisms-of-action as well as the efficacy, safety, and potential clinical applicability. Topics of interest include antiangiogenesis, signal transduction, cytotoxic potentiators, tyrosine kinase inhibitors, immunotherapy, checkpoint inhibitors, biosimilars, antibody drug conjugates, biomarkers, and immuno-oncology specific correlates of safety and efficacy.

**Pain****Acute Pain**

- Increase healthcare provider understanding of non-opioid analgesic use as part of multimodal analgesia to help improve care for patients with postoperative pain.
- Address knowledge gaps related to the optimal management of patients being treated for post-operative pain in outpatient and ambulatory surgical centers

**Chronic Pain**

- Improve awareness of appropriate evidence-based treatment as well as the management of patient expectations in improving care for patients with chronic pain
- Improve patient care by increasing the knowledge, competence, and performance of clinicians who are treating or considering treatment of pain with opioids
- Improve patient care by increasing the healthcare provider's understanding of all available therapeutic options, both prescription and over the counter, in the continuum of pain care

**Parkinson's disease**

Provide learning opportunities on advances in PD research, new treatment development, clinical trials and novel patient care approaches.

Questions? Email [IGLC@pfizer.com](mailto:IGLC@pfizer.com)

**Pulmonary Arterial Hypertension (PAH)**

Improve the understanding of the progression of the pathophysiology and clinical manifestations.

**Rheumatoid Arthritis**

- Improve the care of patients with rheumatoid arthritis (RA) by increasing the knowledge of healthcare providers (HCPs) on the pathophysiology of RA and its implications for mechanism of action of emerging advanced therapies
- Increase HCP knowledge on emerging advanced therapies for inflammatory joint conditions
- Address challenges in the management of RA that may result from an educational gap.

**Sickle Cell**

Improve healthcare provider's knowledge of diagnosis and treatment of sickle cell disease and facilitate enhanced coordination of care and communication between patients with sickle cell disease and healthcare providers.

**Spinal Muscular Atrophy**

Close knowledge gaps regarding the progression of the pathophysiology and clinical manifestations.

**TTR Amyloidosis**

Close knowledge gaps regarding the progression of the pathophysiology, clinical manifestations and survival.

**Urology**

**Overactive bladder**

Increase positive outcomes for both male and female patients with overactive bladder by improving the healthcare provider's knowledge, attitude, communication skills, and resources to provide behavioral modification support and optimal medical treatment.

**USP<797>**

**Pharmaceutical Compounding-Sterile Preparations USP<797>**

- Improve provision of compounded sterile preparations to patients
- Increase awareness of proposed USP <797> and differences from current standard.



**Women's Health**

**Menopause**

Improve healthcare professionals' knowledge and ability to provide individualized, evidence-based, and optimum management of conditions that are prevalent in postmenopausal women, such as vulvar and vaginal atrophy, vasomotor symptoms, and osteoporosis.

**Support for the Global CME/CE/CPD Profession and Under-represented Healthcare Professionals**

This category supports live, MAJOR national and regional conferences whose target audience includes professionals who work in, develop, implement and/or support CME/CE/CPD and QI for healthcare professionals; and live, MAJOR conferences of societies whose members include under-represented or minority healthcare professionals. *NOTE: If an organization requests and receives funding through the IGLC grants portal, they are no longer eligible for funding directly from a Pfizer Country Office, or regional office.*